Sorry, I've looked everywhere but I can't find the page you're looking for.
If you follow the link from another website, I may have removed or renamed the page some time ago. You may want to try searching for the page:
Sorry, I've looked everywhere but I can't find the page you're looking for.
If you follow the link from another website, I may have removed or renamed the page some time ago. You may want to try searching for the page:
I've done a courtesy search for the term ncats nih gov
for you. See if you can find what you're looking for in the list below:
Yesterday I received the following email from NCATS (probably along with thousands of others). Dear Colleagues: This morning, the National Institutes of Health (NIH) announced $12.7 million in awards to match nine academic research groups with a selection of pharmaceutical industry compounds to explore new treatments for patients in eight disease areas, including Alzheimer’s disease, …
A few weeks ago I was interviewed for a podcast by Andrew Wiecek at BioTechniques. I generally have tended to shy away from Podcasts after a previous disaster. But Andrew twisted my arm because the topic was drug repurposing and in particular he asked questions about the NCATS / MRC compounds for repurposing and the …
One has to ask how often history repeats itself. In the case of NCATS its at least every year. Last year a few of us brought to light the case of the drug company (industry) provided compounds looking for a repurposing home on the NCATS website, which oddly enough did not have any structures. This …
I was reminded again yesterday that the NIH is looking for someone to fill a very big job – Associate Director for Data Science – reporting to Francis Collins. Hmm pretty interesting. It is not everyday you see a very prominant opportunity to work with a top scientist in a major organization. Just how big …
Finally, after a little while our paper on the NCATS and MRC industry provided reagents is now in the latest issue of DDT. I will let it speak for itself and we will present on it at the ACS. This pretty much brings us full circle from my first blog on this topic. Needless to say, …
It seems not a week goes by without some mention of the NCATS library of industry provided reagents in the media. I have blogged about this previously and initially I called for us to petition them due to the lack of structures. Honestly I think there should have been someone at NCATS that took a stand and said this is …
Going to stick my little neck out again. I am totally behind the idea of drug companies making their compounds available for researchers to find new uses for rare diseases. But I found out last week that NCATS had put a list of compounds and biologics on their website without releasing structures. This is absolutely nutty (by …
Last tuesday and wednesday (Sept 13-14th) I was very honored to be an attendee at the “Progress Through Partnership: The NINDS 2016 Nonprofit Forum“. My role was to provide an industry perspective on several panels (alongside Dr. Ronald Marcus, Cerecor). There were a large number of rare disease (patients or parent) advocates, academic scientists and …
In full disclosure my better half works for a big pharma, this is not going to hold me back from writing what I am sure everyone is thinking. It saddens me as someone who worked for big pharma (until 2001) to have to write this. We are months into the rapidly escalating catastrophe that is …
I was reminded at the weekend that there are are accessible scientists and there is accessible data and occasionally both. I recently had a reprint request for a paper I co-authored in 1999 and a dataset request for a paper published in 2010. I took time out of my weekend to respond to both scientists …